Cargando…

Safety and Efficacy of Modified FOLFIRINOX in Unresectable or Metastatic Gallbladder Cancer: A Phase II Pilot Study

For unresectable gallbladder cancer (GBC), gemcitabine and platinum is standard combination; however, outcome is poor. We conducted this study to find feasibility of modified flourouracil, oxaliplatin, and irinotecan in this group. MATERIALS AND METHODS: We conducted a prospective, phase II single-a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharma, Atul, Pramanik, Raja, Kumar, Akash, Pathy, Sushmita, Kumar, Sunil, Bhoriwal, Sandeep, Thulkar, Sanjay, Dash, Nihar Ranjan, Pal, Sujoy, Choudhary, Priyanshu, Pawar, Satyajit, Kumar, Rakesh, Gupta, Gaurav
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2021
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8457810/ https://www.ncbi.nlm.nih.gov/pubmed/34086477 http://dx.doi.org/10.1200/GO.20.00657

Ejemplares similares

Long-Term Survivors of Metastatic Colorectal Cancer: A Tertiary Care Centre Experience
por: Sharma, Aparna, et al.
Publicado: (2021)

Patterns of Multimodality Management of Gastric Cancer—Single Institutional Experience of 372 Cases From a Tertiary Care Center in North India
por: Kumar, Sunil, et al.
Publicado: (2022)

Colorectal Cancers in Low- and Middle-Income Countries—Demographic Pattern and Clinical Profile of 970 Patients Treated at a Tertiary Care Cancer Center in India
por: Deo, S. V. S., et al.
Publicado: (2021)

Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center
por: Mittal, Abhenil, et al.
Publicado: (2021)

Efficacy and Safety of Percutaneous Radiological Gastrostomy (PRG) as a Rescue Measure for Enteral Feeding in Patients with Advanced Head, Neck, and Upper Digestive Malignancies
por: Kumar, Mukesh, et al.
Publicado: (2022)

FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
por: Yoo, Changhoon, et al.
Publicado: (2020)

Expression and Clinical Implications of Cysteine Cathepsins in Gallbladder Carcinoma
por: Mehra, Siddharth, et al.
Publicado: (2019)

Spectrum and management of breast cancer patients with variant of uncertain significance mutations at a tertiary care centre in North India
por: Mittal, Abhenil, et al.
Publicado: (2022)

A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma
por: Tansir, Ghazal, et al.
Publicado: (2023)

Metastatic colo-rectal cancer: real life experience from an Indian tertiary care center
por: Sharma, Vinod, et al.
Publicado: (2021)

Porcelain Gallbladder
por: Goel, Apoorv, et al.
Publicado: (2017)

Engraftment Syndrome: A Retrospective Analysis of the Experience at a Tertiary Care Institute
por: Pramanik, Raja, et al.
Publicado: (2019)

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
por: Hosein, Peter J, et al.
Publicado: (2012)

Prognostic Relevance of PDL1 and CA19-9 Expression in Gallbladder Cancer vs. Inflammatory Lesions
por: Rawal, Neetu, et al.
Publicado: (2023)

Feasibility and outcomes of cytoreductive surgery and HIPEC for peritoneal surface malignancies in low- and middle-income countries: a single-center experience of 232 cases
por: Deo, Suryanarayana, et al.
Publicado: (2021)

Nab-paclitaxel: An effective third-line chemotherapy in patients with advanced, unresectable gallbladder cancer
por: Talwar, Vineet, et al.
Publicado: (2020)

Long-Term Outcomes and Safety Trends of Autologous Stem-Cell Transplantation in Non-Hodgkin Lymphoma: A Report From A Tertiary Care Center in India
por: Kumar, Sudhir, et al.
Publicado: (2022)

FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer
por: Adenis, Antoine, et al.
Publicado: (2021)

Induction Therapy with Novel Agents and Autologous Stem Cell Transplant Overcomes the Adverse Impact of Renal Impairment in Multiple Myeloma
por: Kumar, Lalit, et al.
Publicado: (2019)

A multicenter prospective phase II study of first-line modified FOLFIRINOX for unresectable advanced pancreatic cancer
por: Yoshida, Kensaku, et al.
Publicado: (2017)

Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX
por: Shirasu, Hiromichi, et al.
Publicado: (2018)

Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
por: Vogl, Ursula M., et al.
Publicado: (2019)

Locally Advanced, Unresectable Squamous Cell Carcinoma of the Gallbladder
por: Weatherall, Timothy J., et al.
Publicado: (2015)

Microwave-Assisted Catalytic Degradation of Brilliant Green by Spinel Zinc Ferrite Sheets
por: Mishra, Sandhya, et al.
Publicado: (2019)

Gallbladder Perforation: A Prospective Study of Its Divergent Appearance and Management
por: Patel, Gaurav, et al.
Publicado: (2019)

Adult Burkitt lymphoma: An institutional experience with a uniform chemotherapy protocol
por: Patekar, Mukesh, et al.
Publicado: (2018)

Incidental Gallbladder Carcinoma in Gallbladder Polyps: Challenges of Gallbladder Malignancy for an Endemic Population
por: Gautam, Abhishek, et al.
Publicado: (2021)

Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer
por: Kunzmann, Volker, et al.
Publicado: (2014)

Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure
por: Mita, Naoki, et al.
Publicado: (2019)

Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer
por: Hino, Kaori, et al.
Publicado: (2022)

Comparison of MRCP and ERCP in the evaluation of common bile duct and pancreatic duct pathologies
por: Kumar, Anand, et al.
Publicado: (2023)

Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer
por: Mie, Takafumi, et al.
Publicado: (2023)

Impact of First-Line FOLFIRINOX-Induced Peripheral Neuropathy on the Efficacy of Second-Line GnP in Patients with Unresectable Advanced Pancreatic Cancer
por: Sadaka, Shiori, et al.
Publicado: (2022)

Immunoglobulin G4-Related Disease Mimicking Unresectable Gallbladder Cancer
por: Lee, Yoon Suk, et al.
Publicado: (2013)

Complete response after autologous stem cell transplant in multiple myeloma
por: Kumar, Lalit, et al.
Publicado: (2014)

Pigmented Villonodular Synovitis of Ankle Joint – A Case Report
por: Sahu, Santosh Kumar, et al.
Publicado: (2023)

Guiding Principles for Cancer Surgery during the COVID-19 Pandemic
por: Deo, S. V. S., et al.
Publicado: (2020)

Clinical Outcomes of Conversion Surgery after FOLFIRINOX in Patients with Unresectable Advanced Pancreatic Cancer: A Retrospective Cohort Study at a Single Center
por: Mita, Naoki, et al.
Publicado: (2021)

C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel
por: Shirakawa, Tsuyoshi, et al.
Publicado: (2023)

Kimura's disease: A diagnostic dilemma
por: Kumar, Navin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_51dubvcj1pfeu34cta57cg8kqg